Glaxosmithkline Research & Development Limited: clinical-trial pipeline
Glaxosmithkline Research & Development Limited is the sponsor of 3,895 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 186 are not yet finished and 16 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials186
Phase 2/3 and 3961
Countries103
New in 90 days16
Trials by phase
| Phase | Trials |
|---|---|
| Phase 1 | 1,173 |
| Phase 3 | 953 |
| Phase 2 | 836 |
| Not applicable | 532 |
| Phase 4 | 341 |
| Phase 1/2 | 52 |
| Phase 2/3 | 8 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 3,331 |
| Terminated | 257 |
| Withdrawn or not authorised | 114 |
| Recruiting | 72 |
| Active, not recruiting | 70 |
| Not yet recruiting | 44 |
| Unknown | 6 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Infectious disease and vaccines | 1,319 |
| Respiratory | 721 |
| Oncology | 456 |
| Gastroenterology and liver | 339 |
| Rare and genetic diseases | 269 |
| Immunology and rheumatology | 233 |
| Cardiovascular | 192 |
| Metabolic and endocrine (diabetes, obesity) | 188 |
| Neurology | 176 |
| Haematology | 156 |
| Nephrology and urology | 141 |
| Psychiatry and mental health | 141 |
Countries
| Country | Trials |
|---|---|
| United States | 1,575 |
| United Kingdom | 727 |
| Germany | 702 |
| Canada | 535 |
| Spain | 505 |
| France | 405 |
| Australia | 389 |
| Belgium | 377 |
| Italy | 373 |
| Japan | 330 |
| South Korea | 307 |
| Poland | 306 |
| Netherlands | 301 |
| Russia | 285 |
| Argentina | 243 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-13 | New trial posted | A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Event… |
| 2026-10-09 | New trial posted | A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzati… |
| 2026-10-07 | New trial posted | A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy… |
| 2026-10-06 | New trial posted | Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel… |
| 2026-10-06 | New trial posted | A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib |
| 2026-10-06 | New trial posted | J-LINX: Japan LINerixibat eXtension Study |
| 2026-10-01 | New trial posted | A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adul… |
| 2026-09-30 | New trial posted | Prospective Registry of Exposure to Gepotidacin (PREG) |
| 2026-09-28 | New trial posted | A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST) |
| 2026-09-16 | New trial posted | A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Pa… |
| 2026-09-14 | New trial posted | A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in He… |
| 2026-09-11 | New trial posted | A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabote… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05723562 | A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer | Phase 2 | Active, not recruiting | Canada, Germany, Spain, France +6 |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected… | Phase 3 | Active, not recruiting | United Arab Emirates, Argentina, Australia, Belgium +26 |
| NCT06041386 | REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN,… | Phase 4 | Active, not recruiting | Belgium, Canada, Germany, Spain +5 |
| NCT05277051 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Phase 1 | Active, not recruiting | Australia, Canada, China, Spain +5 |
| NCT06534892 | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respirato… | Phase 3 | Active, not recruiting | Australia, Belgium, Canada, Germany +13 |
| NCT04732871 | Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV… | Phase 3 | Active, not recruiting | Germany, Finland, Japan, Taiwan +1 |
| NCT04162210 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Parti… | Phase 3 | Active, not recruiting | Australia, Belgium, Bulgaria, Brazil +15 |
| NCT05565378 | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Meta… | Phase 2 | Active, not recruiting | United Arab Emirates, Argentina, Belgium, Brazil +17 |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, B… | Phase 3 | Active, not recruiting | Australia, Belgium, China, Czechia +12 |
| NCT05263934 | Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophi… | Phase 3 | Active, not recruiting | Argentina, Austria, Belgium, Brazil +16 |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | Phase 2 | Active, not recruiting | Austria, Australia, Belgium, Bulgaria +16 |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractor… | Phase 3 | Active, not recruiting | Australia, Brazil, China, Czechia +13 |
| 2023-504753-12-00 | A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug… | Phase 3 | Active, not recruiting | Belgium, Bulgaria, Czechia, Germany +16 |
| NCT05334368 | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | Phase 3 | Not yet recruiting | Argentina, Australia, Belgium, Brazil +15 |
| NCT04915755 | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 N… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +23 |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Parti… | Phase 1/2 | Active, not recruiting | Australia, Brazil, Canada, Germany +11 |
| NCT02362503 | Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Brazil +21 |
| NCT06572384 | A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Conn… | Phase 3 | Not yet recruiting | Argentina, Australia, Belgium, Brazil +14 |
| NCT06411249 | A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemi… | Phase 4 | Active, not recruiting | Argentina, Brazil, Germany, Spain +7 |
| NCT06613698 | A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged… | Phase 2 | Recruiting | Argentina, Australia, Canada, Germany +13 |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan f… | Phase 1 | Active, not recruiting | Argentina, Australia, Belgium, Brazil +12 |
| NCT06567782 | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untr… | Phase 2 | Active, not recruiting | Belgium, Switzerland, Spain, United Kingdom +2 |
| NCT06694805 | A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Give… | Phase 3 | Active, not recruiting | Argentina, Belgium, Canada, Germany +4 |
| NCT06497504 | Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus… | Phase 2 | Active, not recruiting | Argentina, Brazil, Canada, Spain +6 |
| NCT06716606 | A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Diseas… | Phase 3 | Not yet recruiting | Argentina, Australia, Belgium, China +12 |
Hiring for clinical development
Glaxosmithkline Research & Development Limited has 51 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites: hiring profile of gsk.com.
Website: gsk.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Glaxosmithkline Research & Development Limited clinical trials: 186 open, 961 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/gsk-com/, data as of 2026-10-25.